1. XPO1 Gene Therapy Attenuates Cardiac Dysfunction in Rats with Chronic Induced Myocardial Infarction
- Author
-
José Ramón González-Juanatey, María García-Manzanares, Miguel Rivera, Ana Ortega, Esther Roselló-Lletí, Luis Martínez-Dolz, Manuel Portolés, Estefanía Tarazón, Francisca Lago, Carolina Gil-Cayuela, Producción Científica UCH 2020, UCH. Departamento de Medicina y Cirugía Animal, and UCH. Departamento de Producción y Sanidad Animal, Salud Pública Veterinaria y Ciencia y Tecnología de los Alimentos
- Subjects
Myocardial infarction - Treatment ,Male ,medicine.medical_specialty ,Genetic enhancement ,Fibrillar Collagens ,Corazón - Ventrículos - Enfermedades - Tratamiento ,Myocardial Infarction ,Pharmaceutical Science ,Receptors, Cytoplasmic and Nuclear ,Eukaryotic cells ,Karyopherins ,Placebo ,Ventricular Function, Left ,Cardiac dysfunction ,Rats, Sprague-Dawley ,Fibrosis ,Internal medicine ,Genetics ,Medicine ,Animals ,Myocardial infarction ,Left Ventricular Fractional Shortening ,RNA, Small Interfering ,Ventricular function ,Genetics (clinical) ,Heart - Ventricles - Diseases - Treatment ,Ischemic cardiomyopathy ,Ventricular Remodeling ,business.industry ,Myocardium ,Gene silencing ,medicine.disease ,Myocardial Contraction ,Células eucariotas ,Disease Models, Animal ,RNAi Therapeutics ,Cardiology ,cardiovascular system ,Molecular Medicine ,XPO1 ,Original Article ,RNA Interference ,Infarto de miocardio - Tratamiento ,Cardiology and Cardiovascular Medicine ,business - Abstract
Transcriptomic signature of XPO1 was highly expressed and inversely related to left ventricular function in ischemic cardiomyopathy patients. We hypothesized that treatment with AAV9-shXPO1 attenuates left ventricular dysfunction and remodeling in a myocardial infarction rat model. We induced myocardial infarction by coronary ligation in Sprague-Dawley rats (n = 10), which received AAV9-shXPO1 (n = 5) or placebo AAV9-scramble (n = 5) treatment. Serial echocardiographic assessment was performed throughout the study. After myocardial infarction, AAV9-shXPO1-treated rats showed partial recovery of left ventricular fractional shortening (16.8 ± 2.8 vs 24.6 ± 4.1%, P P P XPO1.
- Published
- 2019